StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
GKSL.BO$135.35+0.59%
Fair $135.35+0.0%

GKSL.BO

GKSL.BO

Healthcare / Medical Care FacilitiesBSE

$135.35

+0.80 (+0.59%)

Fairly Valued+0.0%Fair Value $135.35Fund rank 25/100 · Data gapFallback financials|
SA 52/C
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-46.4M · quality 43.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 11/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

52/100

C

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · GKSL.BOLocal privado en este navegador · GKSL.BO
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$10.7B

P/E

62.7x

↑

EV/EBITDA

30.9x

↑

ROE

6.1%

↑

Gross Margin

88.9%

↑

Debt/Equity

0.12

↓
52-Week Range$135
$98$148

TradingView lightweight chart

GKSL.BO price, volumen y niveles de valoración

Último $137.55Periodo +31.4%
Fair value: $135.35

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

-1.5%

FCF CAGR

—

FCF margin

-191.8%

FCF / Net income

-10.15x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $820.1M · net income $155.0M · FCF $-1.57B

2023-FY → 2026-FY

Gross margin

88.9%+0.3% pts

Operating margin

27.1%+13.6% pts

Net margin

18.9%+11.2% pts

FCF margin

-191.8%-191.8% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$820.1M$820.1M$402.4M$1.03B$857.9M
Net Income$155.0M$155.0M$94.1M$96.8M$66.4M
EBITDA$278.1M$278.1M$167.0M$220.3M$179.3M
EPS2.492.491.191.230.84
Gross Margin88.9%88.9%90.2%89.2%88.6%
Operating Margin27.1%27.1%32.9%14.3%13.5%
Net Margin18.9%18.9%23.4%9.4%7.7%
Balance Sheet
Debt/Equity0.120.120.591.231.06
Current Ratio3.763.76———
Cash Flow
Free Cash Flow$-1.57B$-1.57B$-46.4M$12.1M$1000.00
Returns
ROE6.1%6.1%24.4%43.5%30.2%
Valuation
P/E62.6662.66———
EV/EBITDA30.8630.86———
P/B3.343.34———
Growth & Yield
Revenue Growth103.8%103.8%-61.1%20.6%—
EPS Growth108.6%108.6%-2.8%45.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

69.0%

muy exigente

EPS terminal req.

$12.01

Spread vs growth

39.6%

5Y implied EPS CAGR

42.3%

muy exigente

EPS terminal req.

$14.53

Spread vs growth

66.3%

10Y implied EPS CAGR

25.1%

muy exigente

EPS terminal req.

$23.40

Spread vs growth

83.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +31.4%

Total return

+31.4%

Start / end P/E

87.7x → 55.2x

EPS bridge

1.19 → 2.49

Residual

-40.1%

EPS growth+108.6%
Multiple rerating-37.0%
Dividend+0.0%
Residual / FX / buybacks / cross-term-40.1%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.